[go: up one dir, main page]

OA12099A - 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. - Google Patents

4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. Download PDF

Info

Publication number
OA12099A
OA12099A OA1200200158A OA1200200158A OA12099A OA 12099 A OA12099 A OA 12099A OA 1200200158 A OA1200200158 A OA 1200200158A OA 1200200158 A OA1200200158 A OA 1200200158A OA 12099 A OA12099 A OA 12099A
Authority
OA
OAPI
Prior art keywords
crystal
trifluoromethyl
formula
quinoline
carboxylic acid
Prior art date
Application number
OA1200200158A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Robinson Brostrom
Derek Lawrence Tickner
Original Assignee
Prifzer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prifzer Products Inc filed Critical Prifzer Products Inc
Publication of OA12099A publication Critical patent/OA12099A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
OA1200200158A 1999-11-30 2000-11-14 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. OA12099A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
OA12099A true OA12099A (en) 2006-05-04

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200158A OA12099A (en) 1999-11-30 2000-11-14 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.

Country Status (28)

Country Link
EP (1) EP1246804A1 (fr)
JP (1) JP2003515592A (fr)
KR (1) KR20020058057A (fr)
CN (1) CN1402711A (fr)
AP (1) AP2002002531A0 (fr)
AU (1) AU1048801A (fr)
BG (1) BG106854A (fr)
BR (1) BR0015836A (fr)
CA (1) CA2392979A1 (fr)
CO (1) CO5271716A1 (fr)
EA (1) EA200200510A1 (fr)
EC (1) ECSP003792A (fr)
EE (1) EE200200277A (fr)
GT (1) GT200000199A (fr)
HU (1) HUP0203521A2 (fr)
IL (1) IL149097A0 (fr)
IS (1) IS6338A (fr)
MA (1) MA26845A1 (fr)
MX (1) MXPA02005354A (fr)
NO (1) NO20022558D0 (fr)
OA (1) OA12099A (fr)
PA (1) PA8506301A1 (fr)
PE (1) PE20010904A1 (fr)
PL (1) PL355892A1 (fr)
TN (1) TNSN00231A1 (fr)
TR (1) TR200201446T2 (fr)
UY (1) UY26454A1 (fr)
WO (1) WO2001040190A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2455288A1 (fr) 2001-06-21 2003-01-03 Pfizer Products Inc. Formulations auto-emulsifiantes d'inhibiteurs de la proteine de transfert du cholesterol esterifie (cetp)
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
MXPA04007433A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
EP1469832B2 (fr) 2002-02-01 2016-10-26 Bend Research, Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
EP1920766B1 (fr) * 2002-02-01 2017-08-23 Bend Research, Inc Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
ATE353870T1 (de) 2002-08-30 2007-03-15 Japan Tobacco Inc Dibenzylaminverbindung und deren medizinische verwendung
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7211672B2 (en) 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE461700T1 (de) 2002-12-20 2010-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
KR100729883B1 (ko) * 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
EP2098512A1 (fr) 2003-10-08 2009-09-09 Eli Lilly & Company Composants et procédés de traitement de la dyslopidémie
CA2562082C (fr) * 2004-04-13 2013-06-25 Merck & Co., Inc. Inhibiteurs de la cetp pour le traitement et la prevention de l'atherosclerose
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
WO2006033001A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline
ZA200707498B (en) 2005-02-24 2008-11-26 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2008112166A2 (fr) 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combinaison de metformine r-(+) lipoate et d'agents antihyperlipidémiques pour le traitement de l'hyperglycémie diabétique et de complications diabétiques
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
WO2010075068A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP3174995B1 (fr) 2014-07-30 2020-08-19 F.Hoffmann-La Roche Ag Marqueurs génétiques pour la prédiction de la réactivité à une thérapie avec un agent d'augmentation de hdl ou d'imitation de hdl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (fr) * 1997-02-03 1998-08-06 American Home Products Corporation Derives de l'-1-acyl-1,2-dihydroquinoline substituee en 2 augmentant la concentration en cholesterol hdl
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
TR200201446T2 (tr) 2002-11-21
HUP0203521A2 (hu) 2003-02-28
EE200200277A (et) 2003-10-15
AP2002002531A0 (en) 2002-06-30
ECSP003792A (es) 2002-04-23
UY26454A1 (es) 2001-07-31
MXPA02005354A (es) 2002-12-11
EP1246804A1 (fr) 2002-10-09
WO2001040190A1 (fr) 2001-06-07
PA8506301A1 (es) 2002-08-26
PL355892A1 (en) 2004-05-31
AU1048801A (en) 2001-06-12
MA26845A1 (fr) 2004-12-20
BR0015836A (pt) 2002-08-06
CO5271716A1 (es) 2003-04-30
KR20020058057A (ko) 2002-07-12
PE20010904A1 (es) 2001-09-10
NO20022558L (no) 2002-05-29
GT200000199A (es) 2002-05-23
BG106854A (bg) 2002-12-29
TNSN00231A1 (fr) 2002-05-30
CN1402711A (zh) 2003-03-12
IL149097A0 (en) 2002-11-10
CA2392979A1 (fr) 2001-06-07
IS6338A (is) 2002-04-12
EA200200510A1 (ru) 2002-10-31
NO20022558D0 (no) 2002-05-29
JP2003515592A (ja) 2003-05-07

Similar Documents

Publication Publication Date Title
OA12099A (en) 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.
US6313142B1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
TWI685486B (zh) 製備ｐｄｅ４抑制劑之方法
AU2002358585A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
KR20170102204A (ko) 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
PT87277B (pt) Processo para a preparacao de novos compostos biciclicos e composicoes farmaceuticas compreendendo os mesmos
DE69105786T2 (de) Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen.
CN107522766B (zh) 一类具有抗肿瘤活性的熊果酸喹啉基酰肼衍生物及其制备方法和应用
JP2546919B2 (ja) ９ーアシルアミノテトラヒドロアクリジン誘導体
US6063784A (en) Heteroaryloxyethylamines, method of preparation, application as medicine and pharmaceutical compositions containing them
JPH0474167A (ja) 新規キノリンカルボン酸誘導体、そのエステルおよびその塩
GB2098205A (en) Indoles
MXPA00011855A (en) Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester
WO1997005114A1 (fr) Sulfimides de quinolone ayant une action antagoniste sur les leucotrienes
BE550426A (fr)